• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Premarket Approval (PMA) Summary Review Memos for 180-Day Design Changes

A 180-day supplement is a request for a significant change in components, materials, design, specification, software, color additive, and labeling to an approved premarket application or premarket report.

As a pilot program under the CDRH Transparency Initiative, FDA has begun releasing some summary review memos for 180-day PMA supplements relating to design changes. Links to all available summary review memos can be found in the searchable database linked below:

Premarket Approval (PMA) Summary Review Memos for 180-Day Design Changes Database

This database is updated every Sunday.